Kolon Eyes H1 Korean Filing For Novel Osteoarthritis Cell Therapy
This article was originally published in Clinica
Regenerative medicine specialist Kolon Life Science Inc. has unveiled a financing plan to raise production capacity to prepare for the commercialization of Invossa, also known as TissueGene-C, as it aims to file for an approval in South Korea in the first half of this year.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.